Biosyent Company Profile (CVE:RX)

About Biosyent (CVE:RX)

Biosyent logoBioSyent Inc. is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women's Health Unit, which commercializes pharmaceutical products focused on improving family and women's health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. Cathejell is indicated for surface anesthesia and lubrication for various procedures. RepaGyn helps relieve dryness and promotes healing of the vaginal mucosa. It also manufactures and markets Protect-It, a non-toxic product.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: CVE:RX
  • CUSIP: N/A
  • Web: www.biosyent.com
Capitalization:
  • Market Cap: C$135.79 million
  • Outstanding Shares: 14,648,000
Average Prices:
  • 52 Week Range: C$6.90 - C$9.30
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: N/A
Sales & Book Value:
  • Annual Revenue: C$19.23 million
  • Price / Sales: 7.06
  • Book Value: C$1.34 per share
  • Price / Book: 6.92
Profitability:
  • EBIDTA: C$6.46 million
  • Net Margins: 27.55%
  • Return on Equity: 33.60%
  • Return on Assets: 30.00%
Misc:
  • Average Volume: 6,883 shs.
 

Frequently Asked Questions for Biosyent (CVE:RX)

What is Biosyent's stock symbol?

Biosyent trades on the Canadian Venture Exchange (CVE) under the ticker symbol "RX."

How were Biosyent's earnings last quarter?

Biosyent Inc. (CVE:RX) released its quarterly earnings results on Thursday, May, 25th. The company reported $0.06 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.08 by $0.02. The firm had revenue of $3.82 million for the quarter, compared to the consensus estimate of $4.80 million. Biosyent had a return on equity of 33.60% and a net margin of 27.55%. View Biosyent's Earnings History.

When will Biosyent make its next earnings announcement?

Biosyent is scheduled to release their next quarterly earnings announcement on Wednesday, November, 22nd 2017. View Earnings Estimates for Biosyent.

Who are some of Biosyent's key competitors?

Who are Biosyent's key executives?

Biosyent's management team includes the folowing people:

  • Rene C. Goehrum, Chairman of the Board, President, Chief Executive Officer
  • Alfred D'Souza, Chief Financial Officer
  • Kevin Wilson, Vice President - Sales and Marketing of BioSyent Pharma Inc
  • Douglas R. Larson, Secretary, Director
  • Peter D. Lockhard, Independent Director
  • Paul R. Montador, Independent Director
  • Milton E. Wakefield, Independent Director
  • Stephen Wilton, Independent Director

How do I buy Biosyent stock?

Shares of Biosyent and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Biosyent's stock price today?

One share of Biosyent stock can currently be purchased for approximately C$9.27.


MarketBeat Community Rating for Biosyent (CVE RX)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  24 (Vote Outperform)
Underperform Votes:  28 (Vote Underperform)
Total Votes:  52
MarketBeat's community ratings are surveys of what our community members think about Biosyent and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Biosyent (CVE:RX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for Biosyent (CVE:RX)
Show:
DateFirmActionRatingPrice TargetDetails
2/13/2017Bloom BurtonReiterated RatingAccumulateView Rating Details
(Data available from 9/26/2015 forward)

Earnings

Earnings History for Biosyent (CVE:RX)
Earnings by Quarter for Biosyent (CVE:RX)
Earnings History by Quarter for Biosyent (CVE RX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/22/2017        
5/25/2017Q1 2017C$0.08C$0.06C$4.80 millionC$3.82 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Biosyent (CVE:RX)
2017 EPS Consensus Estimate: $0.34
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.08$0.08$0.08
Q2 20171$0.08$0.08$0.08
Q3 20171$0.10$0.10$0.10
Q4 20171$0.08$0.08$0.08
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Biosyent (CVE:RX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Biosyent (CVE:RX)
Insider Trades by Quarter for Biosyent (CVE:RX)
Insider Trades by Quarter for Biosyent (CVE:RX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/18/2017Douglas Robert LarsonDirectorSell1,300C$9.25C$12,025.00
9/15/2017Douglas Robert LarsonDirectorSell200C$9.25C$1,850.00
9/14/2017Douglas Robert LarsonDirectorSell1,500C$9.20C$13,800.00
6/21/2017Douglas Robert LarsonDirectorSell1,000C$8.10C$8,100.00
6/19/2017Douglas Robert LarsonDirectorSell100C$8.05C$805.00
6/16/2017Milt WakefieldDirectorSell1,000C$7.98C$7,980.00
6/13/2017Milt WakefieldDirectorSell2,000C$7.92C$15,840.00
6/12/2017Douglas Robert LarsonDirectorSell200C$8.05C$1,610.00
6/8/2017Milt WakefieldDirectorSell2,000C$7.93C$15,860.00
6/6/2017Milt WakefieldDirectorSell2,000C$7.74C$15,480.00
6/2/2017Milt WakefieldDirectorSell2,000C$7.80C$15,600.00
3/31/2017Douglas Robert LarsonDirectorSell900C$7.75C$6,975.00
3/23/2017Kevin WilsonInsiderBuy22,576C$7.21C$162,772.96
9/8/2016Douglas Robert LarsonDirectorSell800C$8.35C$6,680.00
3/29/2016Alfred D'souzaInsiderBuy2,000C$7.01C$14,014.00
3/24/2016Alfred D'souzaInsiderBuy3,100C$6.97C$21,591.50
3/24/2016Milt WakefieldDirectorSell2,000C$7.10C$14,200.00
3/23/2016Milt WakefieldDirectorSell2,000C$7.10C$14,200.00
3/21/2016Milt WakefieldDirectorSell4,000C$7.04C$28,160.00
3/16/2016Milt WakefieldDirectorSell2,000C$6.87C$13,740.00
3/9/2016Milt WakefieldDirectorSell4,000C$6.94C$27,776.00
6/17/2015Milt WakefieldDirectorSell4,000C$8.01C$32,040.00
6/15/2015Milt WakefieldDirectorSell4,000C$8.01C$32,040.00
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Biosyent (CVE:RX)
Latest Headlines for Biosyent (CVE:RX)
Source:
DateHeadline
americanbankingnews.com logoDouglas Robert Larson Sells 1,300 Shares of Biosyent Inc. (RX) Stock
www.americanbankingnews.com - September 18 at 4:18 PM
americanbankingnews.com logoInsider Selling: Biosyent Inc. (RX) Director Sells 1,500 Shares of Stock
www.americanbankingnews.com - September 15 at 8:50 PM
americanbankingnews.com logoCormark Brokers Lift Earnings Estimates for Biosyent Inc. (RX)
www.americanbankingnews.com - August 18 at 7:32 AM
globenewswire.com logoBioSyent Releases Q2 and H1 2017 Results - CORRECTION
globenewswire.com - August 16 at 3:58 PM
americanbankingnews.com logoBiosyent Inc. (CVE:RX) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - August 3 at 7:10 AM
americanbankingnews.com logoInsider Selling: Biosyent Inc. (RX) Director Sells 2,000 Shares of Stock
www.americanbankingnews.com - June 13 at 1:32 PM
americanbankingnews.com logoInsider Selling: Biosyent Inc. (RX) Director Sells C$15,860.00 in Stock
www.americanbankingnews.com - June 8 at 4:58 PM
americanbankingnews.com logoMilt Wakefield Sells 2,000 Shares of Biosyent Inc. (RX) Stock
www.americanbankingnews.com - June 6 at 4:50 PM
americanbankingnews.com logoFY2017 Earnings Forecast for Biosyent Inc. Issued By Cormark (RX)
www.americanbankingnews.com - May 29 at 7:24 AM
finance.yahoo.com logoBioSyent Inc. (RX.V)
finance.yahoo.com - May 27 at 7:58 PM
americanbankingnews.com logoBiosyent Inc. (RX) Issues Quarterly Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - May 26 at 8:23 AM
finanznachrichten.de logoFeraMAX(R) Named #1 by Canadian Physicians and Pharmacists for Second Consecutive Year
www.finanznachrichten.de - May 1 at 6:55 PM
finance.yahoo.com logoBioSyent to Present at 2017 Bloom Burton & Co. Healthcare Investor Conference - Yahoo Finance
finance.yahoo.com - April 26 at 5:33 PM
finance.yahoo.com logoBioSyent Extends In-License Agreement for Cathejell(R) - Yahoo Finance
finance.yahoo.com - April 22 at 11:53 AM
americanbankingnews.com logoBiosyent Inc. (RX) Insider Buys C$162,772.96 in Stock
www.americanbankingnews.com - March 29 at 10:11 AM
americanbankingnews.com logoInsider Buying: Biosyent Inc. (RX) Insider Acquires 22,576 Shares of Stock
www.americanbankingnews.com - March 24 at 1:20 PM
finance.yahoo.com logoBioSyent Releases Results for Fourth Quarter and Full Year 2016 - Yahoo Finance
finance.yahoo.com - March 17 at 1:37 AM
benzinga.com logoBioSyent Announces Sale of Shares - Benzinga
www.benzinga.com - December 13 at 8:22 AM
baystreet.ca logoShort Week in U.S. for Thanksgiving
www.baystreet.ca - November 18 at 6:53 PM
finance.yahoo.com logoIIROC Trading Resumption - RX
finance.yahoo.com - May 25 at 1:43 PM
msn.com logoBioSyent to Present at Upcoming Investor Conferences
www.msn.com - April 7 at 1:23 PM

Social

Chart

Biosyent (RX) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by MarketBeat.com Staff